Actualités

The market is underestimating these companies' long-term prospects.

Over the last 7 days, the United States market has risen by 1.2%, contributing to a significant 27% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, identifying stocks that are potentially trading below their estimated value can offer investors opportunities for growth and diversification.

Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded everything else. Bears had been warning about its U.S. patent cliff for years, and when biosimilars finally hit in 2023, the drug went into freefall. Humira sales dropped to just $688 million in Q1 2026, ... AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

ABBV wins EU approval for Aquipta for acute migraine treatment in adults, adding a second approved indication in migraine.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what ... This Is What a $1 Million Dividend Portfolio Pays After Taxes

The United States market has shown robust performance recently, climbing 1.2% in the last week and rising an impressive 27% over the past year, with earnings expected to grow by 17% annually. In this environment, identifying stocks that may be priced below their estimated worth can offer potential opportunities for investors seeking value amidst overall market growth.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become apparent this year.

AbbVie's shareholders can sleep easy.

The United States market has shown impressive performance, rising 1.6% over the last week and climbing 28% in the past year, with earnings forecasted to grow by 17% annually. In light of these conditions, identifying stocks that may be priced below their estimated value can offer opportunities for investors seeking potential growth at a reasonable cost.

AbbVie Inc. (NYSE:ABBV) is one of the top 10 undervalued blue chip stocks analysts recommend for smart investing. AbbVie Inc. (NYSE:ABBV) announced on May 29 authorization by the European Commission (EC) for an expanded label for VENCLYXTO® to include use in combination with acalabrutinib (with or without obinutuzumab), along with use in combination with ibrutinib to […]

AbbVie, CVS Health, and Verizon Communications are all high-yielding stocks with attractive valuations and robust financials.

We recently compiled a list of the 8 Best Immunology Stocks to Buy According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) is among the best immunology stocks. TheFly reported on May 27 that ABBV announced FDA approval of DECNUPAZ (pivekimab sunirine-pvzy) for adults diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and fast-progressing blood […]

Over the last 7 days, the United States market has risen 1.6%, contributing to a 28% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of robust market performance, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for growth and value appreciation.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Glenmark Pharmaceuticals Ltd (BOM:532296) reports robust Q4 growth, achieves debt-free status, and sets ambitious targets for FY27.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

The MIROVA miss dampens prospects for Elahere's near-term label expansion into platinum-sensitive disease.

The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.

The United States market has shown robust growth, with a 1.8% increase over the last week and a remarkable 28% rise over the past year, while earnings are projected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for capitalizing on future growth.

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) is one of the simplest income vehicles in the market: it owns roughly 500 U.S. stocks that pay above-average dividends, weights them by market cap, and passes the cash through to shareholders. VYM tracks the FTSE High Dividend Yield Index, which excludes REITs and screens ... VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

The United States market has shown robust performance, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying stocks that are trading below their estimated value can offer potential opportunities for investors looking to capitalize on market growth while minimizing risk.

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.

By Karen Roman Akari Therapeutics, Plc (Nasdaq: AKTX) said President and CEO Abizer Gaslightwala was part of a Virtual Investor “What This Means” interview highlighting the company’s first abstract acceptance […]

Partnership strategy has produced great pharma bargains—and left the company exposed.

Over the last seven days, the United States market has experienced a 1.3% rise, contributing to a 28% increase over the past year, with earnings forecasted to grow by 17% annually. In such an environment, identifying stocks that are potentially trading below their estimated value can be key for investors looking to capitalize on future growth opportunities.

By Karen Roman VERAXA Biotech AG said it has a securities purchase agreement with an institutional investor for $27.5 million, separate to a $50 million share purchase agreement with Lincoln Park Capital Fund. The company also applied for a Nasdaq listing under the ticker symbol “VRXA” via a combination with Voyager Acquisition Corp. (Nasdaq: VACH) […]

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has become one of the most-owned dividend funds in the country, with $71.6 billion in assets and a 0.06% expense ratio. SCHD currently yields roughly 3.3% and has delivered a 20% year-to-date price return on top of income, outpacing the S&P 500. The key question is whether the distribution ... SCHD’s $71.6 Billion Portfolio Delivers 20% Gains Plus 3.3% Yield This Year